Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the ...

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below The webcast link for the event can be found here: https://viavid ...

NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...

Protagonist claims that disulfide-rich peptides combine benefits of mAbs and small molecules. Ironwood Pharmaceuticals and Protagonist Therapeutics are partnering in a research collaboration that will ...

Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF) IND enabling studies underway, with Phase I ...

Protagonist Therapeutics (PTGX) announced the selection of PN-881, an oral peptide interleukin-17, or IL-17, antagonist, as a development candidate for the treatment of immune-mediated skin diseases.

PN-235 (JNJ-77242113) now expected to advance into multiple Phase 2 clinical studies in 2022, for indications including psoriasis and inflammatory bowel diseases NEWARK, Calif., Dec. 2, 2021 ...

NEWARK, Calif., Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S. Food ...

Protagonist Pictures has upped Alice Vail to head of acquisitions and development alongside a series of key internal promotions across various department and a new addition to its team. Previously ...

Protagonist Pictures, the international sales, finance and production company behind films such as “The Souvenir” Parts I and II and “St Maud,” has announced a significant restructure with an eye to ...